Ursolic acid (UA), a natural pentacyclic triterpenoid carboxylic acid, exhibits diverse biological activities and notable antitumor properties. Lung cancer (LC), a leading malignancy of the respiratory system, is predominantly classified into small cell LC and non-small cell LC. The increasing incidence and mortality rates of LC have spurred considerable interest in the chemo-preventive potential of UA. Accumulating evidence demonstrates that UA markedly inhibits LC cell proliferation and induces apoptosis. Mechanistically, UA induces cell cycle arrest at the G0/G1 phase, thereby suppressing LC cell invasion, migration and tumor growth. Furthermore, UA has shown synergistic effects when combined with other therapeutic agents, including mitotic kinase inhibitors and multifunctional nanomedicines, effectively overcoming drug resistance in LC cells. These multifaceted mechanisms collectively contribute to the chemo-preventive efficacy of UA against LC. Consequently, UA represents a promising candidate for LC prevention and therapy. The present review comprehensively summarizes the anticancer effects and molecular mechanisms of UA in LC, offering insights to guide future research and facilitate the development of innovative therapeutic strategies.
ursolic acidlung cancerchemopreventionrespiratory diseasesphytomedicineYouth Program of the Shandong Provincial Natural Science FoundationZR2023QH079The present study was supported by the Youth Program of the Shandong Provincial Natural Science Foundation (grant no. ZR2023QH079).Introduction
Lung cancer (LC) is among the most prevalent and lethal malignancies worldwide, ranking as the leading cause of cancer-related mortality (1). Early-stage LC is often asymptomatic and difficult to detect, resulting in delayed diagnosis. For patients diagnosed at advanced stages, the five-year survival rate remains dismally low at ~6% (2). Globally, ~1.6 million new LC cases are reported annually (3). In men, LC constitutes the primary cause of both cancer incidence and mortality, whereas among women, its incidence ranks second only to breast and colorectal cancers (4). LC poses a significant public health burden, with major risk factors including exogenous environmental exposures such as tobacco exposure, occupational and environmental carcinogens, and air pollution, as well as endogenous biological factors such as genetic predisposition, chronic lung disease, and hormonal and metabolic factors (5,6). Despite substantial advancements in diagnostic and therapeutic modalities in recent years, the overall prognosis of LC remains poor, particularly for patients with advanced disease (7,8).
Chemoprevention, defined as the use of natural or synthetic agents to prevent, inhibit, delay, or reverse carcinogenesis, has attracted considerable attention as a strategy to combat LC (9). Although various candidate chemo-preventive agents such as vitamin E, isotretinoin and aspirin have been evaluated, none have demonstrated definitive clinical efficacy (10). Natural bioactive compounds, characterized by diverse pharmacological activities and relatively low toxicity, have emerged as promising candidates in cancer prevention and treatment, thereby becoming a central focus of chemoprevention research (11). Ursolic acid (UA; PubChem Compound ID: 64945) is a pentacyclic triterpenoid compound (C30H48O3) widely distributed in various plants, including calendula, lavender, oregano, Melaleuca, sage, apple, rosemary and pear. It has garnered significant scientific interest due to its diverse biological activities (12,13). Previous studies have revealed that UA possesses multifaceted biological activities, including anti-inflammatory (14), antioxidant (15), and anti-obesity effects (16). Additionally, UA exhibits therapeutic potential in a variety of conditions, including diabetes (17), liver diseases (18), cardiovascular diseases (19), gastrointestinal disorders (20) and neurodegenerative diseases (21). Of particular note is its remarkable anticancer potential (22). UA has been demonstrated to inhibit tumor cell proliferation, induce apoptosis, and suppress tumor invasion and metastasis across multiple cancer types, including breast (23), pancreatic (24), prostate (25), colorectal (26), cervical (27) and renal cancers (28).
In LC chemoprevention, UA exerts its effects through multiple molecular mechanisms. Although extensive preclinical evidence supports the potential role of UA in LC prevention, the precise molecular pathways remain to be fully elucidated. Moreover, challenges related to the bioavailability, safety, and clinical efficacy of UA must be addressed to facilitate its translational application. The present review aims to comprehensively summarize the chemo-preventive effects and molecular mechanisms of UA in LC, thereby providing new insights and a theoretical framework for its future application in LC prevention and therapy.
UA and its derivatives
UA is a pentacyclic triterpenoid compound that naturally occurs either as triterpene saponins or in its free acid form (29,30). It is also referred to as urson, malol, prunol, or 3β-3-hydroxy-urs-12-en-28-oic acid (31). UA has the molecular formula C30H48O3, a molecular weight of 456.68 g/mol, and a melting point ranging from 283–285°C (12,32). Its chemical structure comprises five rings-four six-membered and one five-membered-along with multiple hydroxyl and carboxyl functional groups. This distinctive molecular framework confers a broad spectrum of biological activities, including anti-inflammatory, antioxidant, antimicrobial and anticancer effects (33–35). Numerous studies have demonstrated that UA exerts potent anticancer effects across various malignancies (36,37). Its mechanisms of action extend beyond conventional pathways such as apoptosis induction and proliferation inhibition, encompassing unique molecular targets and biological processes. Importantly, UA selectively targets cancer stem cells (CSCs), impairing their self-renewal capacity, which is critical for tumor initiation and recurrence (38). Moreover, UA exhibits context-dependent modulation of autophagy, a process highly relevant to cancer therapy. At low concentrations, UA activates the AMP-activated protein kinase/mammalian target of rapamycin pathway, inducing protective autophagy that facilitates the clearance of damaged cellular components and enhances chemoresistance. Conversely, at high concentrations, UA inhibits autophagy by blocking autophagosome-lysosome fusion, thereby promoting autophagic cell death and augmenting its anticancer efficacy. Beyond autophagy regulation, UA exerts precise anticancer effects by modulating glycolytic metabolism (39), inducing structural modifications (40), and remodeling the tumor microenvironment (41). These multifaceted actions underscore UA as a promising candidate for cancer therapy.
To improve the pharmacological activity and therapeutic potential of UA, various derivatives have been synthesized through chemical modifications targeting its hydroxyl, carboxyl and cyclic backbone moieties. Most reported UA derivatives fall into two principal categories: modifications at C-3/C-28, C-11, C-17 and C-28 positions, and structural alterations involving C-2/C-3 and the A-ring (13,42). Representative examples include UA-piperazine-dithio-carbamate ruthenium (II) polypyridyl complexes, which induce antitumor activity via necrosis (43); corosolic acid (CA), a natural UA derivative that inhibits cancer cell proliferation through β-catenin downregulation (44); UA232, which promotes apoptosis by inducing cell cycle arrest and endoplasmic reticulum (ER) stress (45); and compound 17, a UA-derived small molecule that triggers cancer cell death through macropinocytosis (46). Collectively, these findings suggest that UA derivatives exert anticancer effects through multi-target and multi-pathway mechanisms, enhancing the pharmacological potency and drug-like properties of UA. This not only reinforces its therapeutic efficacy but also offers novel insights for the development of innovative anticancer agents.
Chemo-preventive effects of UA on LCInduction of autophagy and apoptosis in LC cells
Apoptosis plays a pivotal role in tumor development, progression and metastasis, yet cancer cells often evade apoptotic mechanisms to sustain survival (47). Induction of apoptosis facilitates the elimination of potentially harmful or precancerous cells, whereas inhibition of apoptotic pathways contributes to uncontrolled cell proliferation and malignant transformation (48). UA primarily induces apoptosis in LC cells through mitochondria-dependent (MD) pathways, ER stress pathways, and modulation of associated signaling cascades (Fig. 1).
Multiple studies have demonstrated that UA inhibits the proliferation of non-small cell LC (NSCLC) cells in a dose- and time-dependent manner while promoting apoptosis. UA activates caspase-3 and caspase-9, downregulates the anti-apoptotic protein Bcl-2, and upregulates the pro-apoptotic protein Bax, collectively inducing apoptotic cell death in LC cells (49). Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, mediate extracellular matrix (ECM) remodeling, which is implicated in various pathological processes (50). Notably, upregulation of MMP gene expression has been associated with apoptosis induction in NSCLC cells. Lai et al (51) reported that treatment of H460 cells with UA for 24 h led to increased expression of MMP-1, −2, −3, −9, and −10, concomitant with activation of caspase-3, nuclear morphological changes, and DNA fragmentation, thereby promoting apoptosis. Additionally, Gou et al (45) demonstrated that the UA derivative UA232 induces apoptosis in A549 and H460 cells by causing G0/G1 phase cell cycle arrest and upregulating C/EBP-homologous protein, which triggers apoptosis via the ER stress pathway. Consistently, UA has been shown to exert anticancer effects in both A549 and H460 cells by inducing G0/G1 arrest and apoptosis, thereby suppressing tumor growth and progression (52).
Mitochondria are essential organelles involved in regulating cellular functions such as autophagy and apoptosis under stress conditions (53). Chen et al (54) observed that UA increases the expression of apoptosis-inducing factor and endonuclease G in NCI-H292 cells, promoting their release via the MD pathway and triggering apoptosis. To address UA's limited solubility and lack of tumor specificity, Ma et al (55) developed a hyaluronic acid-liposome UA delivery system (HA-Lipo/UA). Their results showed that HA-Lipo/UA upregulated apoptosis-related protein in the TGF-β signaling pathway and p53 expression in A549 cells, activated caspase-3, and enhanced mitochondrial apoptosis, suggesting a promising strategy for targeted LC therapy.
Mitophagy, a selective autophagic process that degrades damaged mitochondria via lysosomal pathways, is another mechanism by which UA exerts anticancer effects. Castrejon-Jiménez et al (56) reported that UA induces mitophagy in A549 cells through a Parkin-independent mechanism, leading to p62 overexpression and subsequent apoptosis. Furthermore, Song et al (57) demonstrated that UA significantly enhances radiosensitivity in NSCLC cells, especially in radiation-resistant cells overexpressing hypoxia-inducible factor 1 alpha (HIF-1α). By reducing the glutathione ratio and downregulating HIF-1α in H1299/M-HIF-1α cells, UA increases radiosensitivity and promotes radiation-induced cell death.
DNA damage repair (DDR) is critical for maintaining genomic stability (58). A strong correlation exists between DNA damage and the initiation of cell death pathways (59). When DNA repair mechanisms are compromised, apoptosis acts as a safeguard to eliminate damaged cells (60). Vaccinia-related kinase 1 (VRK1), a mitotic kinase frequently overexpressed in lung adenocarcinoma, belongs to the nuclear serine-threonine chromatin kinase family (61). UA has been shown to bind the catalytic domain of VRK1, inhibiting its kinase activity. This interference impairs VRK1-mediated 53BP1 foci formation, thereby disrupting DDR and contributing to the therapeutic efficacy of UA against LC (62).
Inhibition of LC cell invasion and migration
Tumor metastasis is a major contributor to the high morbidity and mortality associated with cancer (63). Dysregulation of cancer cell migration critically influences the ability of tumor cells to detach from the primary site and invade surrounding tissues, thereby facilitating metastasis (63).
Proteases play a vital role in cancer progression not only by mediating ECM remodeling but also by regulating the bioavailability of growth factors, pro-angiogenic factors, and cytokines, which collectively promote tumor development through both direct and indirect mechanisms (64). However, the clinical application of UA is limited by its poor water solubility and insufficient tumor-targeting capability (65). To address these challenges, Xu et al (66) developed a novel multifunctional nanoparticle formulation [HA-modified UA and astragaloside IV (AS-IV)-loaded polydopamine nanoparticles (NPs; UA/(AS-IV)@PDA-HA)]. This delivery system significantly enhanced the cytotoxicity of UA and improved its anti-metastatic efficacy in NSCLC cells. Furthermore, UA has been shown to inhibit LC cell invasion in a concentration-dependent manner, with notable suppression of cell migration observed at concentrations between 4 and 16 µmol/l (67).
Epithelial-mesenchymal transition (EMT) is a fundamental cellular program involved in embryonic development, tissue repair and stem cell plasticity, but it also contributes pathologically to fibrosis and cancer metastasis by enhancing cellular motility and invasiveness (68). Experimental studies demonstrated that UA reduces EMT induction in H1975 LC cells triggered by transforming growth factor-β1, thereby inhibiting metastatic potential (69). Additionally, investigations in human NSCLC A549 cells revealed that UA suppresses EMT by inhibiting the nuclear factor Kappa-light-chain-enhancer of activated B Cells (NF-κB) signaling pathway, downregulating astrocyte-elevated gene-1 (AEG-1), and modulating key EMT markers-upregulating epithelial marker E-cadherin while downregulating mesenchymal markers N-cadherin and vimentin. This mechanism effectively curtails tumor cell migration and invasion, underscoring the promise of UA as an anti-metastatic agent in LC treatment (Fig. 2) (70).
Inhibition of LC cell proliferation and growth
Cell proliferation is fundamental to the normal development and homeostasis of multicellular organisms. Dysregulated cell proliferation is a hallmark of tumorigenesis and can also contribute to congenital malformations (71).
Cancer/Testis Antigen Family 45 Member A2 (CT45A2) is implicated as an oncogene in NSCLC and is associated with Epidermal Growth Factor Receptor (EGFR) T790 mutations. The antitumor effects of UA in NSCLC predominantly depend on CT45A2 expression in H1975 cells. UA inhibits CT45A2 transcription by targeting the β-catenin/transcription factor 4 (TCF4) signaling pathway. Specifically, UA negatively regulates the β-catenin/TCF4/CT45A2 axis, thereby suppressing the proliferation of H1975 cells (72). Autophagy-related gene 5 (ATG5) plays a pivotal role in autophagy by participating in the formation of autophagic complexes and autophagosomes, thus amplifying the autophagic response and offering potential therapeutic avenues (73,74). Mutations in ATG5 have been linked to various pathologies. Notably, inhibition of ATG5 via chloroquine (CQ) or siRNA enhances UA's anti-proliferative effects by suppressing autophagy, suggesting that autophagy may serve as a protective mechanism in cancer cells under UA treatment (75).
Cell proliferation involves the biosynthesis of macromolecules such as proteins, lipids and nucleic acids, as well as an increase in cell size and mass. Aberrant regulation of cell proliferation and division contribute to tumor development. Wu et al (76) demonstrated that UA suppresses NSCLC cell proliferation by inducing phosphorylation of stress-activated protein kinase/c-Jun N-terminal kinase and subsequently downregulating Sp1 expression. Furthermore, Way et al (49) reported that UA inhibits LC cell proliferation through modulation of key signaling proteins, including mTOR and AMPK. Their findings indicate that UA activates AMPK in a dose- and time-dependent manner, which in turn suppresses mTOR activity-a central regulator of protein synthesis and cellular proliferation (Fig. 3).
Combination with other anticancer drugs
Chemotherapy remains a cornerstone in the treatment of LC (77,78). However, the emergence of drug resistance constitutes a significant barrier to successful chemotherapy outcomes (79). Cisplatin resistance, in particular, is a major cause of therapeutic failure in patients with LC (80). Recently, UA has attracted increasing attention for its potential to overcome cisplatin resistance in LC (Fig. 4).
Fan et al (81) utilized the A549 human LC cell line as a model for cisplatin-resistant cells and demonstrated that UA treatment inhibited the activation of the Janus kinase 2/signal transducer and activator of transcription 3 (Jak2/Stat3) signaling pathway. This inhibition led to downregulation of pluripotency-associated transcription factors and suppression of CSC enrichment, thereby attenuating chemoresistance.
To improve UA delivery and targeting, Li et al (82) developed a hydrogel-based drug delivery system co-loaded with UA and cisplatin. This platform enhances the targeting of UA to LC cells by facilitating its binding to the LC-specific membrane protein TMEM16A, effectively inhibiting lung adenocarcinoma progression. The hydrogel system thus provides a promising strategy to potentiate UA's therapeutic efficacy in resistant LC.
Furthermore, Chen et al (83) identified the miRNA-149-5p/MyD88 signaling axis as a critical mediator of chemoresistance in NSCLC cells. Their study revealed that UA suppresses this signaling pathway, thereby reducing cancer stemness, overcoming chemotherapy resistance, and ultimately enhancing treatment efficacy in LC.
Novel drug carriers
Currently, most anticancer drugs have the drawback of poor targeting, which can cause irreversible damage to the body during treatment. New drug delivery systems aimed at ensuring drug safety and efficient therapy may become key to enhancing the efficacy of anticancer drugs (84). Research indicates that nanoparticle-based drug delivery systems (Nano-DDS) could potentially resolve the challenges associated with drug administration in cancer therapy (85).
In an experiment by Wu et al (79), a biomimetic red blood cell membrane (RBCM) nano-carrier, UA-loaded NPs coated with RBCM, was developed. This novel biomimetic drug delivery platform enhanced the tumor targeting, stability and biocompatibility of the UA NPs. It addressed the clinical limitations of UA and improved its bioavailability. This innovative biomimetic delivery system significantly improved the anticancer efficacy in advanced NSCLC model, offering a promising strategy for enhancing UA-based treatments. In addition, Xu et al (66) developed a HA-modified UA/AS-IV-loaded polydopamine (PDA) nanomedicine (UA/(AS-IV)@PDA-HA). This nanomedicine effectively enhanced the water solubility and targeting ability of UA. It allows UA to specifically bind to the overexpressed cluster of differentiation 44 on the surface of NSCLC cells. Moreover, the modified nanomedicine significantly improved the cytotoxicity mediated by UA and enhanced its ability to inhibit NSCLC cell proliferation and metastasis. These findings suggest that UA has great potential as an effective targeted anticancer drug for LC therapy. Novel drug delivery systems have greatly enhanced the ability of UA to target LC, enabling precise control that reduces systemic toxicity and improves anticancer efficacy. However, the integration and interaction between targeted therapies and UA in addiction-related oncogenes of NSCLC remain unclear and require further investigation.
Pharmacokinetics of UA
According to the Biopharmaceutics Classification System (BCS), UA is classified as a Class IV drug, characterized by low solubility and low permeability. Although UA demonstrates unique advantages in the treatment of cancers such as LC, its pharmacological efficacy is limited. Due to its lipophilic nature, UA exhibits poor oral bioavailability and has difficulty penetrating biological membranes, thereby reducing its therapeutic effectiveness against tumors (86). To overcome these challenges, Antonio et al (87) developed chitosan (CS)-modified polylactic acid NPs encapsulating UA. Their study showed that this nanoparticle system reduced the average particle size and promoted the amorphous transformation of UA, enabling sustained release. This significantly reduced cytotoxicity in tumor cells and enhanced UA's oral absorption, clearance rate and metabolic efficiency in rat models. Furthermore, Yang et al (88) demonstrated that amorphous UA NPs prepared using the supercritical antisolvent technique effectively improved UA's supersaturation, solubility and absorption. In another study, Yu et al (89) formulated a supramolecular co-amorphous system combining UA and piperine. Through differential scanning calorimetry and scanning electron microscopy, it was confirmed that the co-amorphous system significantly enhanced UA's oral bioavailability and solubility in physiological media compared to its crystalline form.
Regarding drug absorption, high-performance liquid chromatography-mass spectrometry was used to analyze the tissue distribution of UA in rats 1 h after oral administration. The study revealed that UA concentrations were highest in the lungs, followed by the spleen, liver, brain, heart and kidneys, in descending order (90). Additionally, Wang et al (91) found that a novel CS-coated UA liposome achieved significantly higher accumulation at tumor sites in mice compared with conventional UA liposomes and free UA. These findings offer new insights and strategies for enhancing UA's therapeutic efficacy against LC.
In terms of drug metabolism and excretion, research on UA remains relatively limited. Available studies indicate that UA is primarily metabolized in the human body by the hepatic cytochrome P450 (CYP450) enzyme system, along with phase II conjugation reactions. In Caco-2 cells, CYP3A4 and CYP2C9 play key roles in UA metabolism, and the PXR-RXRα pathway has been shown to significantly upregulate CYP2C9 expression, thereby promoting UA biotransformation (92).
In summary, although UA shows promising pharmacokinetic behavior, further studies are needed to fully elucidate its absorption, metabolism and elimination profiles, which will be essential for advancing its clinical application.
Conclusion and outlook
LC, a malignant tumor originating from lung tissue, is one of the most common cancers worldwide and a leading cause of cancer-related mortality (93,94). UA plays a significant role in the treatment of LC, with mechanisms that include inhibiting cell proliferation, invasion and migration, and reducing drug resistance. These effects involve signaling pathways such as β-catenin, β-catenin/TCF4/CT45A2, NF-κB, Jak2/Stat3, and the regulation of related genes such as ATG5, CT45A2, MMP and AEG-1, as well as the expression of proteins such as Bcl-2, Bax, upregulation of E-cadherin, downregulation of N-cadherin, vimentin, mTOR and sp1, alongside the involvement of proteases and kinases such as caspase-3, caspase-9, urokinase, cathepsin B, AMPK and VRK1 (Table I).
Due to the limited water solubility, poor targeting ability, and drug resistance of UA (95), the development of novel DDS, including Nano-DDS and hydrogel-based delivery systems, has greatly addressed these issues. These innovations significantly enhance the delivery efficiency, targeting ability and bioavailability of UA, improving the effectiveness of monotherapy and boosting the antitumor effect through synergistic strategies. Furthermore, Ram Kumar Pandian et al (96) found that polyhydroxybutyrate NPs could deliver UA, enhancing its stability and bioactivity, thus improving the treatment of tumors. In another study by Sharma et al (97), HA-UA conjugates were used to prepare PTX-loaded HA-UA NPs, which significantly inhibited tumor cell proliferation in experimental models, offering new ideas and methods for combined chemotherapy delivery. If these two delivery systems are applied to the treatment of LC, they might yield unforeseen effects and become a new direction for future research. In addition, smoking as an important factor affecting LC is detrimental to the whole process of carcinogenesis. It has been identified that polycyclic aromatic hydrocarbons in cigarettes can affect the metabolism of drugs by key drug-metabolizing enzymes of cytochrome P450 and isoforms of the glucuronosyltransferase family, shortening the duration of drug action by accelerating the metabolism of related drugs and thus affecting therapeutic efficacy (98). In addition, Zevin et al (99) found that smoking significantly upregulated CYP2E1 activity, increasing the rate of metabolizing drugs while activating carcinogens and increasing the risk of disease. Whether smoking affects the metabolism and utilization of natural active ingredients, such as UA, has not been confirmed by relevant experiments, and the authors will further explore this issue in future studies.
Although UA shows remarkable therapeutic potential in LC treatment, there are still some limitations: First, low bioavailability: Its poor water solubility results in low absorption and bioavailability in the body. Second, lack of clinical trial data: Most studies on UA in LC remain at the laboratory stage, lacking large-scale clinical trials to support its safety and efficacy. In particular, clinical evidence for UA combination chemotherapy in non-small cell carcinoma remains low and a distant dream. Third, Dose and administration challenges: In clinical application, determining the appropriate dose is crucial. A very low dose may result in ineffective treatment, while a very high dose could cause toxicity. Further experimental research is needed to optimize dosing and administration methods. Fourth, drug interactions: UA may interact with other drugs, influencing their metabolism and therapeutic effects. Identifying interactions with other drugs is one of the future research directions. Fifth, side effects and toxicity: While UA is considered a relatively safe natural compound, high doses or prolonged use may still produce toxicity and side effects, which need further investigation. Sixth, individual differences: Patients may have different responses to UA based on factors such as genetic background, tumor type, stage and overall health. Hence, it is essential to avoid generalizing treatment approaches.
In conclusion, while UA has made significant progress in non-clinical research, some issues and limitations remain. In the future, the authors will focus research on the cultivation of real animal cells, to deepen the analysis of their multi-target regulatory networks and develop efficient delivery systems, to promote the clinical translation of UA and its derivatives, and ultimately to realize the leap from cellular evidence to human disease intervention (Fig. 5).
Acknowledgements
Not applicable.
Availability of data and materials
Not applicable.
Authors' contributions
ZL wrote the manuscript and drew the pictures. QC and ZC collected and organized literature. TP and JB proofread the manuscript. FM are fully responsible for the study designing, research fields, drafting, and finalizing the manuscript. All authors read and approved the final version of the manuscript. Data authentication is not applicable.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesFrydrychowiczMKuszelŁDworackiGBudna-TukanJMicroRNA in lung cancer-a novel potential way for early diagnosis and therapyJ Appl Genet64459477202310.1007/s13353-023-00750-236821071JuangYRAngLSeowWJPredictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: A systematic review and meta-analysisSci Rep154259202510.1038/s41598-024-83875-640038330ZhangMMaCLSR promotes cell proliferation and invasion in lung cancerComput Math Methods Med20216651907202133763152SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalABrayFGlobal Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin71209249202133538338SiegelRLMillerKDFuchsHEJemalACancer statistics, 2021CA Cancer J Clin71733202133433946PallisAGSyrigosKNLung cancer in never smokers: Disease characteristics and risk factorsCrit Rev Oncol Hematol88494503201310.1016/j.critrevonc.2013.06.01123921082JonesGSBaldwinDRRecent advances in the management of lung cancerClin Med (Lond)18(Suppl 2)S41S46201810.7861/clinmedicine.18-2-s4129700092LimRBEnd-of-life care in patients with advanced lung cancerTher Adv Respir Dis10455467201610.1177/175346581666092527585597KohYCHoCTPanMHRecent advances in cancer chemoprevention with phytochemicalsJ Food Drug Anal281437202010.1016/j.jfda.2019.11.00131883602BadeBCDela CruzCSLung cancer 2020: Epidemiology, etiology, and preventionClin Chest Med41124202010.1016/j.ccm.2019.10.00132008623SimilieDMindaDBoraLKroškinsVLugiņinaJTurksMDeheleanCADanciuCAn update on pentacyclic triterpenoids ursolic and oleanolic acids and related derivatives as anticancer candidatesAntioxidants (Basel)13952202410.3390/antiox1308095239199198PironiAMde AraújoPRFernandesMASalgadoHRNChorilliMCharacteristics, biological properties and analytical methods of ursolic acid: A reviewCrit Rev Anal Chem488693201810.1080/10408347.2017.139042529039968MlalaSOyedejiAOGondweMOyedejiOOUrsolic acid and its derivatives as bioactive agentsMolecules242751201910.3390/molecules2415275131362424KashyapDSharmaATuliHSPuniaSSharmaAKUrsolic acid and oleanolic acid: Pentacyclic terpenoids with promising Anti-inflammatory activitiesRecent Pat Inflamm Allergy Drug Discov102133201610.2174/1872213X1066616071114390427531153LiobikasJMajieneDTrumbeckaiteSKursvietieneLMasteikovaRKopustinskieneDMSavickasABernatonieneJUncoupling and antioxidant effects of ursolic acid in isolated rat heart mitochondriaJ Nat Prod7416401644201110.1021/np200060p21648406JayaprakasamBOlsonLKSchutzkiRETaiMHNairMGAmelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas)J Agric Food Chem54243248200610.1021/jf052034216390206YuSGZhangCJXuXESunJHZhangLYuPFUrsolic acid derivative ameliorates Streptozotocin-induced diabestic bone deleterious effects in miceInt J Clin Exp Pathol836813690201526097549SundaresanARadhigaTPugalendiKVEffect of ursolic acid and Rosiglitazone combination on hepatic lipid accumulation in high fat diet-fed C57BL/6J miceEur J Pharmacol741297303201410.1016/j.ejphar.2014.07.03225149666ErdmannJKujacińskiMWicińskiMBeneficial effects of ursolic acid and its derivatives-focus on potential biochemical mechanisms in cardiovascular conditionsNutrients133900202110.3390/nu1311390034836155ShiYLengYLiuDLiuXRenYZhangJChenFResearch advances in protective effects of ursolic acid and oleanolic acid against gastrointestinal diseasesAm J Chin Med49413435202110.1142/S0192415X2150019133622215ChenCAiQShiAWangNWangLWeiYOleanolic acid and ursolic acid: Therapeutic potential in neurodegenerative diseases, neuropsychiatric diseases and other brain disordersNutr Neurosci26414428202310.1080/1028415X.2022.205195735311613SandhuSSRouzSKKumarSSwamyNDeshmukhLHussainAHaqueSTuliHSUrsolic acid: A pentacyclic triterpenoid that exhibits anticancer therapeutic potential by modulating multiple oncogenic targetsBiotechnol Genet Eng Rev39729759202310.1080/02648725.2022.216225736600517IqbalJAbbasiBAAhmadRMahmoodTKanwalSAliBKhalilATShahSAAlamMMBadshahetHUrsolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implicationsBiomed Pharmacother108752756201810.1016/j.biopha.2018.09.09630248543LinJHXuJJLiuXFLiuWHWangYFLiZSWangLWWangWUrsolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine-resistant human pancreatic cancer cellsPhytother Res3420532066202010.1002/ptr.666932185829MengYLinZMGeNZhangDLHuangJKongFUrsolic acid induces apoptosis of prostate cancer cells via the PI3K/Akt/mTOR pathwayAm J Chin Med4314711486201510.1142/S0192415X1550083426503559ZhangHZhangXMaXWangXUrsolic acid in colorectal cancer: Mechanisms, current status, challenges, and future research directionsPharmacol Rep777286202510.1007/s43440-024-00684-439617815GuoJLHanTBaoLLiXMMaJQTangLPUrsolic acid promotes the apoptosis of cervical cancer cells by regulating endoplasmic reticulum stressJ Obstet Gynaecol Res45877881201910.1111/jog.1391930632222CaiCZhiYXieCGengSSunFJiZZhangPWangHTangJUrsolic acid-downregulated long noncoding RNA ASMTL-AS1 inhibits renal cell carcinoma growth via binding to HuR and reducing vascular endothelial growth factor expressionJ Biochem Mol Toxicol37e23389202310.1002/jbt.2338937300450NamdeoPGidwaniBTiwariSJainVJoshiVShuklaSSPandeyRKVyasATherapeutic potential and novel formulations of ursolic acid and its derivatives: An updated reviewJ Sci Food Agric10342754292202310.1002/jsfa.1242336597140MaXBaiYLiuKHanYZhangJLiuYHouXHaoEHouYBaiGUrsolic acid inhibits the cholesterol biosynthesis and alleviates high fat Diet-induced hypercholesterolemia via irreversible inhibition of HMGCS1 in vivoPhytomedicine103154233202210.1016/j.phymed.2022.15423335671633Fernández-HernándezAMartinezARivasFGarcía-MesaJAParraAEffect of the solvent and the sample preparation on the determination of triterpene compounds in two-phase olive-mill-waste samplesJ Agric Food Chem6342694275201510.1021/jf506171y25773914LiuJPharmacology of oleanolic acid and ursolic acidJ Ethnopharmacol495768199510.1016/0378-8741(95)90032-28847885IkedaYMurakamiAOhigashiHUrsolic acid: An anti- and pro-inflammatory triterpenoidMol Nutr Food Res522642200810.1002/mnfr.20070038918203131WangXXiongWWangXQinLZhongMLiuYXiongYYiXWangXZhangHUrsolic acid attenuates cholestasis through NRF2-mediated regulation of UGT2B7 and BSEP/MRP2Naunyn Schmiedebergs Arch Pharmacol39722572267202410.1007/s00210-023-02733-w37812240LuanMWangHWangJZhangXZhaoFLiuZMengQAdvances in Anti-inflammatory activity, mechanism and therapeutic application of ursolic acidMini Rev Med Chem22422436202210.2174/138955752166621091311352234517797ShanmugamMKDaiXKumarAPTanBKSethiGBishayeeAUrsolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studiesBiochem Pharmacol8515791587201310.1016/j.bcp.2013.03.00623499879KhwazaVOyedejiOOAderibigbeBAUrsolic Acid-based derivatives as potential anti-cancer agents: An updateInt J Mol Sci215920202010.3390/ijms2116592032824664KangDYSpNJangKJJoESBaeSWYangYMAntitumor effects of natural bioactive ursolic acid in embryonic cancer stem cellsJ Oncol20226737248202210.1155/2022/673724835222644WangSChangXZhangJLiJWangNYangBPanBZhengYWangXOuHWangZUrsolic acid inhibits breast cancer metastasis by suppressing glycolytic metabolism via activating SP1/Caveolin-1 signalingFront Oncol11745584202110.3389/fonc.2021.74558434568078PandaSSThangarajuMLokeshwarBLUrsolic acid analogs as potential therapeutics for cancerMolecules278981202210.3390/molecules2724898136558113ZhangNLiuSShiSChenYXuFWeiXXuYSolubilization and delivery of Ursolic-acid for modulating tumor microenvironment and regulatory T cell activities in cancer immunotherapyJ Control Release320168178202010.1016/j.jconrel.2020.01.01531926193ChenHGaoYWangAZhouXZhengYZhouJEvolution in medicinal chemistry of ursolic acid derivatives as anticancer agentsEur J Med Chem92648655201510.1016/j.ejmech.2015.01.03125617694JiangHWeiJHLinCYLiangGBHeRJHuangRZMaXLHuangGBZhangYUrsolic acid-piperazine-dithiocarbamate ruthenium(II) polypyridyl complexes induced necroptosis in MGC-803 cellsMetallomics14mfac072202210.1093/mtomcs/mfac07236149330KimJHKimYHSongGYKimDEJeongYJLiuKHChungYHOhSUrsolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of beta-catenin degradationFood Chem Toxicol678795201410.1016/j.fct.2014.02.01924566423GouWLuoNWeiHWuHYuXDuanYBiCNingHHouWLiYUrsolic acid derivative UA232 evokes apoptosis of lung cancer cells induced by endoplasmic reticulum stressPharm Biol58707715202010.1080/13880209.2020.179401332726164SunLLiBSuXChenGLiYYuLLiLWeiWAn ursolic acid derived small molecule triggers cancer cell death through hyperstimulation of macropinocytosisJ Med Chem6066386648201710.1021/acs.jmedchem.7b0059228678485LiuXQiMLiXWangJWangMCurcumin: A natural organic component that plays a Multi-faceted role in ovarian cancerJ Ovarian Res1647202310.1186/s13048-023-01120-636859398NedopekinaDAGubaidullinRROdinokovVNMaximchikPVZhivotovskyBBel'skiiYPKhazanovVAManuylovaAVGogvadzeVSpivakAYMitochondria-targeted betulinic and ursolic acid derivatives: Synthesis and anticancer activityMedchemcomm819341945201710.1039/C7MD00248C30108714WayTDTsaiSJWangCMHoCTChouCHChemical constituents of Rhododendron formosanum show pronounced growth inhibitory effect on non-small-cell lung carcinoma cellsJ Agric Food Chem62875884201410.1021/jf404243p24447325Abdel-HamidNMAbassSAMatrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targetingMol Biol Rep4865256538202110.1007/s11033-021-06635-z34379286LaiMYLeungHWYangWHChenWHLeeHZUp-regulation of matrix metalloproteinase family gene involvement in ursolic acid-induced human lung non-small carcinoma cell apoptosisAnticancer Res27145153200717352226KangDYSpNLeeJMJangKJAntitumor effects of ursolic acid through mediating the inhibition of STAT3/PD-L1 signaling in Non-small cell lung cancer cellsBiomedicines9297202110.3390/biomedicines903029733805840NunnariJSuomalainenAMitochondria: In sickness and in healthCell14811451159201210.1016/j.cell.2012.02.03522424226ChenCJShihYLYehMYLiaoNCChungHYLiuKLLeeMHChouPYHouHYChouJSChungJGUrsolic acid induces apoptotic cell death through AIF and endo G release through a Mitochondria-dependent pathway in NCI-H292 human lung cancer cells in vitroIn Vivo33383391201910.21873/invivo.1148530804116MaTZhouJLiJChenQHyaluronic Acid-modified liposomes for ursolic Acid-targeted delivery treat lung cancer based on p53/ARTS-mediated mitochondrial apoptosisIran J Pharm Res22e131758202310.5812/ijpr-13175838116552Castrejón-JiménezNSLeyva-ParedesKBaltierra-UribeSLCastillo-CruzJCampillo-NavarroMHernández-PérezADLuna-AnguloABChacón-SalinasRCoral-VázquezRMEstrada-GarcíaIUrsolic and oleanolic acids induce mitophagy in A549 human lung cancer cellsMolecules243444101910.3390/molecules24193444SongBZhangQYuMQiXWangGXiaoLYiQJinWUrsolic acid sensitizes radioresistant NSCLC cells expressing HIF-1α through reducing endogenous GSH and inhibiting HIF-1αOncol Lett13754762201710.3892/ol.2016.546828356955SmithGAlholmZColemanRLMonkBJDNA damage repair Inhibitors-combination therapiesCancer J27501505202110.1097/PPO.000000000000056134904813WangJYDNA damage and apoptosisCell Death Differ810471048200110.1038/sj.cdd.440093811687882KainaBDNA damage-triggered apoptosis: Critical role of DNA repair, double-strand breaks, cell proliferation and signalingBiochem Pharmacol6615471554200310.1016/S0006-2952(03)00510-014555233Campillo-MarcosIGarcía-GonzálezRNavarro-CarrascoELazoPAThe human VRK1 chromatin kinase in cancer biologyCancer Lett503117128202110.1016/j.canlet.2020.12.03233516791KimSHRyuHGLeeJShinJHarikishoreAJungHYKimYSLyuHNOhEBaekNIUrsolic acid exerts anti-cancer activity by suppressing Vaccinia-related kinase 1-mediated damage repair in lung cancer cellsSci Rep514570201510.1038/srep1457026412148HanTKangDJiDWangXZhanWFuMXinHBWangJBHow does cancer cell metabolism affect tumor migration and invasion?Cell Adh Migr7395403201310.4161/cam.2634524131935AffaraNIAndreuPCoussensLMDelineating protease functions during cancer developmentMethods Mol Biol539132200910.1007/978-1-60327-003-8_119377975LiuJOleanolic acid and ursolic acid: Research perspectivesJ Ethnopharmacol1009294200510.1016/j.jep.2005.05.02415994040XuFLiMQueZSuMYaoWZhangYLuoBLiYZhangZTianJCombined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancerJ Mater Chem B1134533472202310.1039/D2TB02328H37009696HuangCYLinCYTsaiCWYinMCInhibition of cell proliferation, invasion and migration by ursolic acid in human lung cancer cell linesToxicol In Vitro2512741280201110.1016/j.tiv.2011.04.01421539908LamouilleSXuJDerynckRMolecular mechanisms of epithelial-mesenchymal transitionNat Rev Mol Cell Biol15178196201410.1038/nrm375824556840RuanJSZhouHYangLWangLJiangZSSunHWangSMUrsolic acid attenuates TGF-β1-induced epithelial-mesenchymal transition in NSCLC by targeting integrin αVβ5/MMPs signalingOncol Res27593600201910.3727/096504017X1505172385870628911340LiuKGuoLMiaoLBaoWYangJLiXXiTZhaoWUrsolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cellsAnticancer Drugs24494503201310.1097/CAD.0b013e328360093b23511428JesudasonECConnellMGFernigDGLloydDALostyPDCell proliferation and apoptosis in experimental lung hypoplasiaJ Pediatr Surg35129133200010.1016/S0022-3468(00)80029-910646790YangKChenYZhouJMaLShanYChengXWangYZhangZJiXChenLUrsolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutationsBr J Pharmacol17646094624201910.1111/bph.1479331322286ChangotraHKaurSYadavSSGuptaGLParkashJDusejaAATG5: A central autophagy regulator implicated in various human diseasesCell Biochem Funct40650667202210.1002/cbf.374036062813BaevaMECamara-LemarroyCThe role of autophagy protein Atg5 in multiple sclerosisMult Scler Relat Disord79105029202310.1016/j.msard.2023.10502937778158WangMYuHWuRChenZYHuQZhangYFGaoSHZhouGBAutophagy inhibition enhances the inhibitory effects of ursolic acid on lung cancer cellsInt J Mol Med4618161826202032901853WuJZhaoSTangQZhengFChenYYangLYangXLiLWuWHannSSActivation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cellsJ Exp Clin Cancer Res3499201510.1186/s13046-015-0215-926362062HigginsMJEttingerDSChemotherapy for lung cancer: The state of the art in 2009Expert Rev Anticancer Ther913651378200910.1586/era.09.11519827996SouhamiRLDefining the role of chemotherapy in non-small-cell lung cancerAnn Oncol6317318199510.1093/oxfordjournals.annonc.a0591767619744WuTYanDHouWJiangHWuMWangYChenGTangCWangYXuHBiomimetic red blood cell membrane-Mediated nanodrugs loading ursolic acid for targeting NSCLC therapyCancers (Basel)144520202210.3390/cancers1418452036139680ShenMXuZXuWJiangKZhangFDingQXuZChenYInhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathwayJ Exp Clin Cancer Res38149201910.1186/s13046-019-1161-830961670FanLWangXChengCWangSLiXCuiJZhangBShiLInhibitory effect and mechanism of ursolic acid on Cisplatin-induced resistance and stemness in human lung cancer A549 cellsEvid Based Complement Alternat Med20231307323202310.1155/2023/130732337089712LiSGuoXLiuHChenYWanHKangXQinJGuoSUrsolic acid, an inhibitor of TMEM16A, co-loaded with cisplatin in hydrogel drug delivery system for multi-targeted therapy of lung cancerInt J Biol Macromol277134587202410.1016/j.ijbiomac.2024.13458739122079ChenQLuoJWuCLuHCaiSBaoCLiuDKongJThe miRNA-149-5p/MyD88 axis is responsible for ursolic Acid-mediated attenuation of the stemness and chemoresistance of non-small cell lung cancer cellsEnviron Toxicol35561569202010.1002/tox.2289131855318Pérez-HerreroEFernández-MedardeAAdvanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapyEur J Pharm Biopharm935279201510.1016/j.ejpb.2015.03.01825813885FuSLiGZangWZhouXShiKZhaiYPure drug Nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapyActa Pharm Sin B1292106202210.1016/j.apsb.2021.08.01235127374JinhuaWUrsolic acid: Pharmacokinetics process in vitro and in vivo, a mini reviewArch Pharm (Weinheim)352e1800222201910.1002/ardp.20180022230663087AntonioEDos Reis Antunes JuniorOMarcanoRGDJVDiedrichCda Silva SantosJMachadoCSKhalilNMMainardesRMChitosan modified poly (lactic acid) nanoparticles increased the ursolic acid oral bioavailabilityInt J Biol Macromol172133142202110.1016/j.ijbiomac.2021.01.04133450338YangLSunZZuYZhaoCSunXZhangZZhangLPhysicochemical properties and oral bioavailability of ursolic acid nanoparticles using supercritical anti-solvent (SAS) processFood Chem132319325201210.1016/j.foodchem.2011.10.08326434296YuDKanZShanFZangJZhouJTriple strategies to improve oral bioavailability by fabricating coamorphous forms of ursolic acid with piperine: Enhancing Water-solubility, permeability, and inhibiting cytochrome P450 isozymesMol Pharm1744434462202010.1021/acs.molpharmaceut.0c0044332926628ChenQLuoSZhangYChenZDevelopment of a liquid chromatography-mass spectrometry method for the determination of ursolic acid in rat plasma and tissue: Application to the pharmacokinetic and tissue distribution studyAnal Bioanal Chem39928772884201110.1007/s00216-011-4651-x21249342WangMZhaoTLiuYWangQXingSLiLWangLLiuLGaoDUrsolic acid liposomes with chitosan modification: Promising antitumor drug delivery and efficacyMater Sci Eng C Mater Biol Appl7112311240201710.1016/j.msec.2016.11.01427987679LeiPLiZHuaQSongPGaoLZhouLCaiQUrsolic acid alleviates neuroinflammation after intracerebral hemorrhage by mediating microglial pyroptosis via the NF-κB/NLRP3/GSDMD pathwayInt J Mol Sci2414771202310.3390/ijms24191477137834220SunKWuHZhuQGuKWeiHWangSLiLWuCChenRPangYGlobal landscape and trends in lifetime risks of haematologic malignancies in 185 countries: Population-based estimates from GLOBOCAN 2022EClinicalMedicine83103193202510.1016/j.eclinm.2025.10319340256772BrayFLaversanneMSungHFerlayJSiegelRLSoerjomataramIJemalAGlobal cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin74229263202438572751WuBYParksLMChemical studies on ursolic acidJ Am Pharm Assoc Am Pharm Assoc42603606195310.1002/jps.303042100613096400Ram Kumar PandianSKunjiappanSPavadaiPSundarapandianVChandramohanVSundarKDelivery of ursolic acid by polyhydroxybutyrate nanoparticles for cancer therapy: In silico and in vitro studiesDrug Res (Stuttg)727281202210.1055/a-1640-000934666392SharmaRYadavVJhaSDigheSJainSUnveiling the potential of ursolic acid modified hyaluronate nanoparticles for combination drug therapy in triple negative breast cancerCarbohydr Polym338122196202410.1016/j.carbpol.2024.12219638763723O'MalleyMKingANConteMEllingrodVLRamnathNEffects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancerJ Thorac Oncol9917926201410.1097/JTO.000000000000019124926542ZevinSBenowitzNLDrug interactions with tobacco smoking. An updateClin Pharmacokinet36425438199910.2165/00003088-199936060-0000410427467
Molecular targets regulated by UA and their effects on cellular autophagy and apoptosis. UA, ursolic acid; HA-Lipo/UA, hyaluronic acid-liposome UA; GSH, glutathione; MMP, matrix metalloproteinase; ARTS, apoptosis-related protein in the TGF-β signaling pathway; HIF, hypoxia-inducible factor; PD-L1, programmed death-ligand 1; VRK1, vaccinia-related kinase 1; Chop, C/EBP-homologous protein. Figure created using Adobe Illustrator 2024 (v28.0), Adobe Inc.
Figure 1. Molecular targets regulated by UA and their effects on cellular autophagy and apoptosis. UA, ursolic acid; HA–Lipo / UA, hyaluronic acid–liposome UA; GSH, glutathione; MMP, matrix metallopro...
Molecular targets regulated by UA and their effects on cell invasion and migration. UA, ursolic acid; MMP, matrix metalloproteinase; AEG-1, astrocyte-elevated gene-1. Figure created using Adobe Illustrator 2024 (v28.0), Adobe Inc.
Figure 2. Molecular targets regulated by UA and their effects on cell invasion and migration. UA, ursolic acid; MMP, matrix metalloproteinase; AEG–1, astrocyte–elevated gene–1. Figure created using Ad...
Molecular targets regulated by UA and their effects on cell proliferation. UA, ursolic acid. Figure created using Adobe Illustrator 2024 (v28.0), Adobe Inc.
Figure 3. Molecular targets regulated by UA and their effects on cell proliferation. UA, ursolic acid. Figure created using Adobe Illustrator 2024 (v28.0), Adobe Inc.
Molecular targets regulated by UA and their impact on attenuating drug resistance. UA, ursolic acid; miR, microRNA. Figure created using Adobe Illustrator 2024 (v28.0), Adobe Inc.
Figure 4. Molecular targets regulated by UA and their impact on attenuating drug resistance. UA, ursolic acid; miR, microRNA. Figure created using Adobe Illustrator 2024 (v28.0), Adobe Inc.
Mechanisms associated with the chemoprotective effect of UA for the treatment of lung cancer. UA, ursolic acid. Figure created using Adobe Illustrator 2024 (v28.0), Adobe Inc.
Figure 5. Mechanisms associated with the chemoprotective effect of UA for the treatment of lung cancer. UA, ursolic acid. Figure created using Adobe Illustrator 2024 (v28.0), Adobe Inc.
Mechanism of action of ursolic acid in lung cancer.